Holen Sie sich die Stockscreener-App
0.3276
1.36%
0.0044
Handel nachbörslich:
.33
0.0024
+0.73%
Schlusskurs vom Vortag:
$0.3232
Offen:
$0.3206
24-Stunden-Volumen:
47,081
Relative Volume:
0.46
Marktkapitalisierung:
$7.58M
Einnahmen:
$81.89M
Nettoeinkommen (Verlust:
$-55.20M
KGV:
-0.1215
EPS:
-2.6959
Netto-Cashflow:
$-67.40M
1W Leistung:
-1.59%
1M Leistung:
-3.05%
6M Leistung:
-36.85%
1J Leistung:
-87.54%
1-Tages-Spanne:
$0.3128
$0.3339
1-Wochen-Bereich:
$0.3128
$0.3499
52-Wochen-Spanne:
$0.29
$3.05
Turnstone Biologics Corp Stock (TSBX) Company Profile
Firmenname
Turnstone Biologics Corp
Sektor
Branche
Telefon
347-897-5988
Adresse
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Vergleichen Sie TSBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.3276 | 7.70M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-10-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-16 | Eingeleitet | SVB Securities | Market Perform |
| 2023-08-15 | Eingeleitet | BofA Securities | Buy |
| 2023-08-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Turnstone Biologics Corp Aktie (TSBX) Neueste Nachrichten
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Turnstone Biologics Reports Q1 Loss Amid Strategic Shift - TipRanks
Turnstone Biologics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights - The Manila Times
Turnstone Biologics Reports Q1 2025 Financial Results and Updates on Strategic Alternatives - Nasdaq
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent - Bluefield Daily Telegraph
Turnstone Biologics (NASDAQ:TSBX) Shares Up 0.8% – Still a Buy? - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.29 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.29 - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.33 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.33 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.34 By Investing.com - Investing.com South Africa
Turnstone Biologics stock plunges to 52-week low of $0.34 - Investing.com
Q1 EPS Forecast for Turnstone Biologics Decreased by Analyst - Defense World
Analysts Set Expectations for TSBX Q1 Earnings - Defense World
Turnstone Biologics Corp: Strategic Partnerships and Financial Position Justify Hold Rating - TipRanks
Turnstone Biologics Reports 2024 Financial Results - TipRanks
Turnstone Biologics moves to Nasdaq Capital Market By Investing.com - Investing.com South Africa
Turnstone Biologics moves to Nasdaq Capital Market - Investing.com
Turnstone Biologics Corp. SEC 10-K Report - TradingView
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Turnstone Biologics Cuts Losses by $3.6M as Company Pivots Strategy - Stock Titan
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Growth in Short Interest - Defense World
Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.35 By Investing.com - Investing.com Australia
Turnstone Biologics stock plunges to 52-week low of $0.35 - Investing.com India
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering, Business Wires News - AsiaOne
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Large Drop in Short Interest - Defense World
Turnstone Biologics Stock Hits 52-Week Low at $0.36 Amid Challenges - Investing.com Australia
Turnstone Biologics halts TIDAL-01 development, seeks alternatives - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 - MSN
Turnstone Biologics stock plunges to 52-week low of $0.4 By Investing.com - Investing.com Canada
Cautious Hold on Turnstone Biologics Amid TIL Therapy Challenges and Strategic Alternatives - TipRanks
Analysts Offer Predictions for TSBX FY2024 Earnings - Defense World
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Leerink Partnrs Weighs in on TSBX FY2024 Earnings - Armenian Reporter
Turnstone Biologics (NASDAQ:TSBX) Stock Rating Lowered by Piper Sandler - Defense World
Finanzdaten der Turnstone Biologics Corp-Aktie (TSBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):